EGFR expression rate in NPC is reported to be about 80%, and the overexpression relates to inferior PFS and OS, leading to the expectation that Cmab will also show efficacy in NPC patients (4, 5). The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.